These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 6257384)

  • 41. Mouse mammary tumor virus associated antigens and superantigens--immuno-molecular correlates of neoplastic progression.
    Wei WZ; Gill RF; Wang H
    Semin Cancer Biol; 1993 Jun; 4(3):205-13. PubMed ID: 8391342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retrovirus-host interactions. The mouse mammary tumor virus model.
    Acha-Orbea H
    Medicina (B Aires); 1997; 57 Suppl 2():43-52. PubMed ID: 9567343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High incidence of mammary tumors in mice with inherited asplenia carriers for the nude gene.
    Lozzio BB; Lopez DM; Coulson P; Lair SV
    Cancer Res; 1979 May; 39(5):1529-33. PubMed ID: 218729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro detection of immune responses to MTV-induced mammary tumors: qualitative differences in response detected by time studies.
    Blair PB; Lane MA
    J Immunol; 1975 Jan; 114(1 Pt 1):17-23. PubMed ID: 163276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of lymphoid cells separated from mammary tumors in blastogenesis and Winn assays.
    Blazar BA; Laing CA; Miller FR; Heppner GH
    J Natl Cancer Inst; 1980 Aug; 65(2):405-10. PubMed ID: 6931258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular immunity to mammary tumor virus in normal and tumor-bearing C3H/HeN mice.
    Tagliabue A; Herberman RB; McCoy JL
    Cancer Res; 1978 Aug; 38(8):2279-84. PubMed ID: 208765
    [No Abstract]   [Full Text] [Related]  

  • 47. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses.
    Watson GA; Lopez DM
    J Immunol; 1995 Sep; 155(6):3124-34. PubMed ID: 7673727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complexity of factors in sera of different mice that affect MTV-induced mammary tumor cells.
    Blair PB; Lane MA; Mar P
    J Immunol; 1976 Mar; 116(3):610-4. PubMed ID: 176267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunologic studies with mouse mammary tumor viruses: comparative studies with spontaneous mammary tumor cell vaccines from five inbred mouse strains.
    Girardi AJ; Dion AS; Holben JA
    J Natl Cancer Inst; 1985 Jan; 74(1):105-12. PubMed ID: 2982052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mouse mammary tumor virus infections: viral expression and tumor risk.
    Altrock BW; Cardiff RD
    J Natl Cancer Inst; 1979 Oct; 63(4):1075-80. PubMed ID: 225501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levels of mammary tumor virus in hormone-dependent and -independent mouse mammary tumor cells.
    Sluyser M; Nouwen T; Hilgers J; Calafat J
    Cancer Res; 1977 Jul; 37(7 Pt 1):1986-90. PubMed ID: 193632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro studies on splenocyte cytotoxicity against syngeneic mammary carcinomas of mice. 1. Reactivity of splenocytes from mice bearing mammary tumors against the corresponding and against other neoplasms.
    More R; Yron I; Weiss DW
    Isr J Med Sci; 1978 Jan; 14(1):146-61. PubMed ID: 204609
    [No Abstract]   [Full Text] [Related]  

  • 53. Observations on the question of horizontal transmission of mouse mammary tumor virus.
    Moore DH; Holben JA
    Cancer Res; 1978 Aug; 38(8):2455-7. PubMed ID: 208768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exogenous mouse mammary tumor virus (MMTV) infection induces endogenous MMTV sag expression.
    Xu L; Wrona TJ; Dudley JP
    Virology; 1996 Jan; 215(2):113-23. PubMed ID: 8560758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
    Palmer LD; Saha B; Hodes RJ; Abe R
    J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mouse mammary tumor virus (MMTV), a retrovirus that exploits the immune system. Genetics of susceptibility to MMTV infection.
    Ross SR; Dzuris JL; Golovkina TV; Clemmons WC; van den Hoogen B
    Medicina (B Aires); 1997; 57 Suppl 2():34-42. PubMed ID: 9567342
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T cells bearing Vbeta8 are preferentially infected with exogenous mouse mammary tumor virus.
    Upragarin N; Nishimura H; Wajjwalku W; Ando Y; Nagafuchi S; Watanabe T; Yoshikai Y
    J Immunol; 1997 Sep; 159(5):2189-95. PubMed ID: 9278306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stimulation of immune mechanisms against mammary tumors by incomplete T cell depletion.
    Roubinian JR; Lane MA; Slomich M; Blair PB
    J Immunol; 1976 Nov; 117(5 Pt.2):1767-73. PubMed ID: 186535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppressor cells in mice with murine mammary tumor virus-induced mammary tumors. I. Inhibition of mitogen-induced lymphocyte stimulation.
    Rudczynski AB; Mortensen RF
    J Natl Cancer Inst; 1978 Jan; 60(1):205-11. PubMed ID: 203703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.